The safety and efficacy of a preparation with treosulfan/thiotepa/ fludarabine were explored in 20 thalassaemia patients given allogeneic marrow transplantation. Seventeen patients were transplanted from unrelated donors after receiving anti-thymocyte globulin. The regimen was well tolerated. Two patients experienced secondary graft failure; one died of acute graft-versus-host disease. Cumulative incidence (95% confidence interval, CI) of transplantation-related mortality and graft failure was 5% (95% CI, 0-34%) and 11% (95% CI, 3-43%), respectively. Two-year probability of survival and thalassaemia-free survival was 95% (95% CI, 85-100%) and 85% (95% CI, 66-100%), respectively. This regimen might find elective application in patients at high risk of developing life-threatening complications. © 2008 The Authors.

Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major / Bernardo, M. E.; Zecca, M.; Piras, E.; Vacca, A.; Giorgiani, G.; Cugno, C.; Caocci, G.; Comoli, P.; Mastronuzzi, A.; Merli, P.; La Nasa, G.; Locatelli, F.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 143:4(2008), pp. 548-551. [10.1111/j.1365-2141.2008.07385.x]

Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major

Bernardo M. E.
Primo
Formal Analysis
;
2008-01-01

Abstract

The safety and efficacy of a preparation with treosulfan/thiotepa/ fludarabine were explored in 20 thalassaemia patients given allogeneic marrow transplantation. Seventeen patients were transplanted from unrelated donors after receiving anti-thymocyte globulin. The regimen was well tolerated. Two patients experienced secondary graft failure; one died of acute graft-versus-host disease. Cumulative incidence (95% confidence interval, CI) of transplantation-related mortality and graft failure was 5% (95% CI, 0-34%) and 11% (95% CI, 3-43%), respectively. Two-year probability of survival and thalassaemia-free survival was 95% (95% CI, 85-100%) and 85% (95% CI, 66-100%), respectively. This regimen might find elective application in patients at high risk of developing life-threatening complications. © 2008 The Authors.
2008
Conditioning regimen
Haematopoietic stem cell transplantation
Thalassaemia major
Toxicity
Treosulfan
Adolescent
Adult
Busulfan
Child
Child, Preschool
Drug Therapy, Combination
Female
Graft Rejection
Graft vs Host Disease
Humans
Infant
Male
Myeloablative Agonists
Thiotepa
Transplantation Conditioning
Treatment Outcome
Vidarabine
Young Adult
beta-Thalassemia
Hematopoietic Stem Cell Transplantation
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/106143
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 61
  • ???jsp.display-item.citation.isi??? 52
social impact